Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
CAMEO: Canadian Methotrexate and Etanercept Outcome Study
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 258
- Registration Number
- NCT00654368
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 350
- Registration Number
- NCT00650078
- Locations
- 🇵🇱
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Klinika Reumatologii i Ukladowych Chorób Tkanki Lacznej, Lublin, Poland
🇭🇺Debreceni Egyetem, III. Belgyógyászati Klinika, Reumatológiai Tanszék, Debrecen, Hungary
🇭🇺MÁV Kórház Szolnok, Reumatológiai Osztály, Szolnok, Hungary
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Phase 1
Completed
- Conditions
- Colon CancerRectal CancerColorectal CancerMetastatic Colorectal CancerOncology
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 53
- Registration Number
- NCT00630786
Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
Phase 1
Completed
- Conditions
- Locally Advanced or Metastatic, Unresectable Soft Tissue SarcomaSarcomaSoft Tissue Sarcoma
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 134
- Registration Number
- NCT00626704
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Metastatic Colorectal CancerColon CancerColorectal CancerRectal Cancer
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2014-04-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 202
- Registration Number
- NCT00625651
- Locations
- 🇺🇸
Research Site, Vancouver, Washington, United States
Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
Phase 2
Terminated
- Conditions
- Cancer of PancreasCancer of the PancreasPancreas CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3
- Registration Number
- NCT00613730
Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Phase 2
Completed
- Conditions
- MDSThrombocytopeniaMyelodysplastic Syndromes
- Interventions
- Drug: PlaceboBiological: Romiplostim
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 250
- Registration Number
- NCT00614523
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
Phase 3
Completed
- Conditions
- OsteoarthritisRheumatoid ArthritisChronic Regional Pain SyndromeChronic Soft Tissue PainChronic Low Back Pain
- Interventions
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 179
- Registration Number
- NCT00613106
- Locations
- 🇺🇸
PRA International, San Diego, California, United States
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 260
- Registration Number
- NCT00606450
- Locations
- 🇨🇦
Innovaderm, Montreal, Quebec, Canada
🇨🇦Dr Yves Poulin, Quebec City, Quebec, Canada
🇨🇿Department of Dermatovererology, Praha, Czechia
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 19
- Registration Number
- NCT00604682
- Locations
- 🇺🇸
University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States
🇺🇸NYU School of Medicine, New York, New York, United States
🇺🇸Mt Sinai School of Medicine, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath